Afamelanotide continues promising results

Written by on December 21, 2009 in melanotan with 1 Comment

Clinuvel is announcing more positive results with its trial of the melanin boosting drug afamelanotide for the disease polymorphic light eruption (PLE).

Even though this condition is rare and it is a stretch to say that treating rosacea with this drug is a given, it is still interesting to follow the development of this drug.

Today’s press release relate to the continuing good results, this time from the Phase III (randomised, double blind, placebo controlled) clinical trials.

The Rosacea Question

For those who do suffer from PLE, simple events like venturing outside can be a trauma. Environmental trauma is experienced by some rosacea sufferers so for them, developments like afamelanotide are interesting.

Just to what extent those with severe sun triggers will experience relief from afamelanotide is completely up for question. How easily rosacea sufferers will be able to be prescribed this drug is another open question.

Clinuvel announces PLE Phase III preliminary results

Friday 18th December 2009, Melbourne, Australia

Trial in polymorphic light eruption (PLE) to support the final registration dossier of afamelanotide

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it has
obtained preliminary results in its multicenter randomised double-blind placebo controlled PLE study (CUV015) evaluating the safety and efficacy of afamelanotide 20 mg implants. PLE is a recurrent seasonal UV-related skin disorder seen mostly in fair-skinned patients (10-20% incidence) in the northern hemisphere.

Related Articles

Read more about: melanotan

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

1 Reader Comment

  1. Chris says:

    Treatment, yes. Cure, no (sadly)

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.